Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach.
With GH001, we have completed two Phase 1 clinical trials (GH001-HV-101 and GH001-HV-103) in healthy volunteers and a Phase 1/2 clinical trial (GH001-TRD-102) in patients with treatment-resistant depression (TRD).
Ongoing trials with GH001 include a Phase 2b clinical trial in patients with TRD, and Phase 2 open-label trials in patients with bipolar II disorder and postpartum depression.
GH002 is our mebufotenin product candidate formulated for administration via a proprietary intravenous administration approach. In Q4 2023 we successfully completed a Phase 1 clinical trial of GH002 (GH002-HV-105) in 64 healthy volunteers.
GH003 is our mebufotenin product candidate formulated for administration via a proprietary intranasal administration approach. GH003 is currently in preclinical development.
Mebufotenin for inhalation administration
Trial Name: GH001-TRD-201; Status: Ongoing; ClinicalTrials.gov ID: NCT05800860
Trial Name: GH001-PPD-203; Status: Ongoing; ClinicalTrials.gov ID: NCT05804708
Swipe to view the full table
Mebufotenin for i.v. administration
Trial Name: GH002-HV-105; Status: Completed; ClinicalTrials.gov ID: NCT05753956
Swipe to view the full table
Mebufotenin for nasal administration
Swipe to view the full table